ILP4 and InR regulate paclitaxel-induced hypersensitivity differently in Drosophila larvae

Area of Science:

• Neuroscience
• Molecular Biology
• Pharmacology

Background:

• Paclitaxel (PTX) is a chemotherapy drug known to cause nerve damage and pain hypersensitivity.
• The precise molecular mechanisms underlying PTX-induced nociceptive hypersensitivity are not fully understood.

Purpose of the Study:

• To investigate the molecular and genetic basis of paclitaxel-induced nociceptive hypersensitivity.
• To explore the role of specific signaling pathways and molecules in PTX effects on sensory neurons.

Main Methods:

• Dose-dependent administration of PTX to Drosophila larvae.
• Live imaging of peripheral thermal nociceptors to observe dendritic morphology.
• Genetic manipulation using RNA interference (RNAi) and gene mutants (ILP4, InR).

Main Results:

• PTX induced dose-dependent thermal hypersensitivity and altered dendritic morphology (hyper-sprouting and beading) in nociceptors.
• PTX-induced hypersensitivity was independent of previously known acute injury pathways.
• Insulin-like peptide 4 (ILP4) was required for PTX hypersensitivity, but the insulin receptor (InR) in nociceptors did not mediate this effect.
• Salivary glands were identified as a likely source of ILP4.

Conclusions:

• PTX-induced hypersensitivity involves a complex interplay of neuronal and molecular factors, including ILP4.
• There is a dissociation between hypersensitivity and neuronal structural changes (dendritic morphology) in response to PTX.
• The findings suggest a novel signaling pathway involving ILP4, separate from InR in nociceptors, contributes to PTX-induced pain sensitization.